20 articles
A completed clinical trial tests whether a prebiotic blend can boost Akkermansia muciniphila and support weight management in metabolic syndrome.
Small pilot study explores whether restoring gut bacteria can break the cycle of recurrent UTIs in women.
A completed trial tested whether probiotic and prebiotic supplementation could reduce premature aging-related inflammation in people living with HIV.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Small pilot study tests whether acarbose, a diabetes medication, can slow aging processes in healthy older adults through microbiome changes.
Study explores how genetic variants influence whether plant-based or animal-based diets trigger inflammation and alter gut microbiome.
Clinical trial tests safety of combined prebiotic-probiotic supplement in 32 healthy participants over 5 months.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A completed trial explores whether a low-fibre diet can ease intestinal dysmotility — one of the most debilitating but overlooked symptoms of mitochondrial disease.
Small study tests synbiotic supplements to combat age-related immune decline in healthy elderly adults.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
82-person study reveals how Mediterranean eating patterns modify intestinal microbes to improve cardiovascular and metabolic markers.
University study tests whether combining probiotics with prebiotics can restore healthy gut bacteria and immune function in people over 65.
A completed RCT tests whether 1-hour pathogen detection paired with antimicrobial stewardship slashes broad-spectrum antibiotic days in HAP patients.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
Small trial explores how popular greens supplement affects microbiome and blood nutrient markers in healthy adults over 7 weeks.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Small study explores how health education affects gut bacteria and physical decline in seniors over 12 months.
A completed French trial investigated whether rogue antibodies targeting ghrelin and alpha-MSH disrupt appetite regulation in eating disorder patients.
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
